Ketamine-Assisted Psychotherapy: A Practical Guide for Medical Providers
Lynne A. McInnes, MD and Jessicca Yu, NP
Ketamine, an NMDA receptor antagonist, has now been FDA approved for treatment-resistant depression (TRD) in the intranasal form and is also available as an oral, intravenous, and intramuscular agent. This session will describe a rationale for the use of ketamine-assisted psychotherapy (KAP) for TRD, providing a historical context and examples of current theoretical stances. We will discuss which patients are good candidates for this therapy and provide extensive case examples. Practical issues related to KAP, including reimbursement and insurance as well as prevention of medication misuse, will also be addressed.
Systematic Strategies for Managing Common Side Effects (Instead of Stopping or Switching the Medication)
Rajnish Mago, MD
Preventing and managing common side effects is an essential skill for psychopharmacologists, but one that is relatively neglected. Clinicians will learn a series of actionable strategies (basic, intermediate, and advanced) for the prevention and management of common side effects that lead to nonadherence to medication, including nausea, sexual dysfunction, excessive sweating, orthostatic hypotension, etc.
Extinguishing the Flames: The Role of Inflammation in Mental Health and Anti-Inflammatory Interventions
Saundra Jain, MA, PsyD, LPC and Charles Raison, MD
Inflammation was once considered a topic of interest primarily for non-mental health practitioners. However, the tides have changed as we now know, based on scientific evidence, that inflammation is a significant issue in many psychiatric conditions. This session will address the scientific evidence supporting the role of inflammation in mental health. This session will focus on both pharmacologic and nonpharmacologic anti-inflammatory interventions.